Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. by Wood, Georgina et al.
Wood, Georgina; Grenader, Tal; Nash, Stephen; Adams, Richard;
Kaplan, Richard; Fisher, David; Maughan, Tim; Bridgewater, John
(2017) Derived neutrophil to lymphocyte ratio as a prognostic factor
in patients with advanced colorectal cancer according to RAS and
BRAF status. Anti-Cancer Drugs, 28 (5). pp. 546-550. ISSN 0959-
4973 DOI: https://doi.org/10.1097/cad.0000000000000488
Downloaded from: http://researchonline.lshtm.ac.uk/4650207/
DOI: 10.1097/cad.0000000000000488
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
  
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with 
advanced colorectal cancer according to RAS and BRAF status: a post-hoc 
analysis of the MRC COIN study. 
Georgina Wooda Tal Grenaderb; Stephen Nashc; Richard Adamsd; Richard Kaplane; David 
Fishere; Tim Maughanf and John Bridgewaterg 
a University College London Hospital, London, UK 
b Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel.  
c Cancer Research UK & UCL Cancer Trials Centre, London, UK. 
d Institute of Cancer & Genetics, Cardiff University School of Medicine Velindre Hospital, Cardiff, UK. 
e MRC Clinical Trials Unit at UCL, London , UK. 
f CRUK/MRC Oxford Institute for Radiation, Oxford, UK. 
g UCL Cancer Institute, London, UK 
 
 
 
 
E mail addresses: 
Georgina Wood    georgina.wood3@nhs.net 
Tal Grenader   talgrenader65@hotmail.com 
Stephen Nash  stephen.nash@lshtm.ac.uk  
Richard Adams  Richard.Adams@wales.nhs.uk  
Richard Kaplan   r.kaplan@ucl.ac.uk  
David Fisher  d.fisher@ucl.ac.uk  
Tim Maughan  tim.maughan@oncology.ox.ac.uk  
John Bridgewater  j.bridgewater@ucl.ac.uk  
 
 
Corresponding author: 
Georgina Wood 
Department of Oncology, University College London Hospital, First Floor Central, 250 Euston 
Road, NW1 2PG 
 
E-mail: georgina.wood3@nhs.net 
  
Abstract 
 
Background The phase III COntinuous or INtermittent (COIN) trial failed to demonstrate a 
benefit in overall survival of cetuximab in combination with chemotherapy for patients with 
metastatic colorectal cancer (mCRC). High derived neutrophil to lymphocyte ratio (dNLR) has 
been shown to be prognostic in patients with mCRC. The aim of this analysis is to evaluate 
dNLR as a predictive biomarker of the survival according to RAS and BRAF mutations status 
within the COIN trial. 
Methods:  A post-hoc exploratory analysis of the COIN trial arms A and B was performed. All 
patients with available white blood cell (WBC) and neutrophil data were analysed.  The dNLR 
was calculated using a formula which has previously demonstrated predictive power in can-
cer patients: dNLR=ANC/(WBC-ANC). A high dNLR was defined as a value of >2.22. dNLR was 
correlated with clinical outcomes using Kaplan-Meier and cox regression analysis. 
Results: A total of 1603 patients were assigned to the oxaliplatin based chemotherapy (arm 
A, N=815) or oxaliplatin based chemotherapy plus cetuximab (arm B, N=815) arms. There was 
a strong association between dNLR level and overall survival using Kaplan-Meier analysis. In 
all mutation groups, dNLR<2.2 was associated with better overall survival (OS) compared to 
dNLR≥2.2. Median OS in patients with wild type disease (dNLR<2.2 vs dNLR≥2.2) was 22.8 vs 
13.1 months (HR 1.33); 16.9  vs 11.8  months (HR 1.36) in patients with RAS mutant tumours; 
and 12.6 vs 6.8 (HR 1.67) in patients with BRAF mutant tumours. 
In patients with dNLR<2.2, the median OS was 19.2 months in arm A compared to 18.0 
months in arm B (HR 1.11). Among patients with dNLR≥2.2, the median OS was 13.0 months 
in arm A compared to 13.1 months in arm B (HR of 0.96). 
  
Conclusion: dNLR is strongly prognostic for survival in all mutations groups. dNLR does not 
predict for benefit from the addition of cetuximab. 
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Background 
The Continuous or Intermittent (COIN) phase III randomised study demonstrated a prognos-
tic effect of BRAF, KRAS, and NRAS mutations on the outcome of patients with advanced col-
orectal cancer. However, benefit of additional cetuximab treatment to oxaliplatin based 
chemotherapy in first line treatment of these patients was not proved. [1] Comparable stud-
ies have demonstrated mixed response outcome data for patients with RAS wild-type tu-
mours in the context of chemotherapy combinations with epidermal growth factor receptor 
(EGFR) inhibitors. [2-5] To further clarify sub-group sensitivity to EGFR inhibition prospective 
testing is needed. [6-7]  
The tumour microenvironment and the inflammatory response have been shown to play a 
vital role in cancer development. Measurable serum parameters of C-reactive protein, neu-
trophil/lymphocyte ratio (NLR) and platelet-lymphocyte ratio have been associated with poor 
outcomes in patients with colorectal cancer. [8-10] NLR is a marker of host inflammation and 
may reflect cytokine activation and therefore be a surrogate marker of more aggressive dis-
ease. A recently reported meta-analysis of 100 studies comprising 40559 patients with vari-
ous solid tumours, found that NLR >4 was associated with poorer OS (HR 1.81; 95% CI = 1.67 
to 1.97; p < 0.001). This effect was observed in all of the disease sites, subgroups and stages. 
[11] Within this meta-analysis, 6 prospective studies, contained a total of 1817 patients with 
mCRC.  
The COIN trial did not collect lymphocyte count data, however the derived NLR (dNLR) has 
been shown to possess similar prognostic value. [12]  In a previous analysis of the COIN trial 
we have determined that dNLR is predictive of survival when administering intermittent ver-
sus continuous treatment. [13] In this study, we examined dNLR as a prognostic factor and 
  
assessed its’ predictive power regarding the potential benefit of EGFR inhibition, particularly 
in the RAS and BRAF populations. 
 
Methods 
The phase III COIN trial was undertaken by the Medical Research Council Clinical Trials Unit 
and was overseen by an independent trial steering committee. The trial was approved by na-
tional research ethics committees in the UK and Ireland and both the Medicines and 
Healthcare Regulatory Agency and Irish Medicines Board. The trial design and eligibility crite-
ria have been reported previously. [1] 
COIN trial’s primary objective was to assess the effect of the addition of EGFR-targeted mon-
ocloncal antibody (cetuximab) to continuous oxaliplatin and fluoropyrimidine combination 
chemotherapy on survival. Shortly after COIN completed recruitment, external evidence 
showed that anti-EGFR antibodies were unlikely to benefit mCRC patients whose tumours 
carry KRAS mutations. [14]  
Treatment allocation was non-blinded and randomly assigned (1:1) to the control arm of con-
tinuous oxaliplatin based (oxaliplatin plus capecitabine or oxaliplatin plus fluorouracil and fo-
linic acid) chemotherapy (arm A) or continuous chemotherapy plus cetuximab (arm B). The 
treatment was continued until progression of disease, development of cumulative toxicities 
or patient choice. [1] 
We have performed a post-hoc exploratory analysis of the prognostic and predictive power 
of dNLR in the COIN trial arms A and B. All patients with available white blood cell (WBC) and 
  
neutrophil data were analysed. Unfortunately, lymphocyte data was not collected at patient 
entry to the COIN trial.  
 
Derived Neutrophil/lymphocyte ratio (dNLR) calculation 
WBC and absolute neutrophil count (ANC) were collected on all patients at enrolment to the 
COIN trial. dNLR was calculated using this formula - dNLR=ANC/(WBC-ANC). [8,12] 
 
Statistical methods 
All statistical analyses were performed by the Cancer Research UK and University College 
London Cancer Trials Centre. Stats version 12.1 was used to analyse data.  
A high dNLR was defined as ≥2.2. dNLR was correlated with clinical outcomes including over-
all survival (OS), progression-free survival (PFS) and objective response rate (ORR). Kaplan-
Meier survival curves were generated based on dNLR. Comparison between groups was per-
formed using cox-regression analysis adjusted for treatment, age, sex, tumour status (re-
sected, unresected, or local recurrence), primary site (colon, rectum, rectosigmoid junction, 
multiple growths), liver-only metastases (yes vs no), number of metastatic sites (0, 1, 2, ≥3), 
platelets (<400,000 vs ≥400,000 µL), alkaline phosphatase (<300 vs ≥ 300 U/L). Prognostic 
value was assessed with ROC analysis, using one year survival as the outcome, and reporting 
the estimate of AUC. [13] 
 
Results 
  
1,630 of 2,445 patients in the COIN trial were randomised to arm A (chemotherapy) and arm 
B (chemotherapy plus cetuximab). Our total cohort was 1,603 patients (accounting for 98.3% 
of the total study population), excluding 9 patients with no WBC and ANC data and 18 pa-
tients with other missing data. The median value of dNLR was 2.2; baseline characteristics 
within each dNLR group are shown in table 1. 
 
dNLR as a prognostic marker 
There was a strong association between dNLR level and outcome. We found that patients 
with dNLR ≥ 2.2 had a hazard ratio (HR) of 1.35 (95% CI 1.20-1.52; p<0.001) for OS (figure 1) 
and 1.25 (95% CI 1.13-1.40; p<0.001) for PFS. 
In patients with dNLR<2.2, the median overall survival was 19.2 months in arm A and 18.0 
months in arm B - HR 1.11 (figure 2a). Among patients with dNLR≥2.2, the median overall 
survival was 13.0 months in arm A compared to 13.1 months in arm B- HR 0.96 (figure2b).  A 
differential treatment effect between the two dNLR groups was not seen (p = 0.21). 
The AUC for dNLR was 63.9% (95% CI 61.1-66.7). Dichotomising the data at the median value 
of dNLR (2.2) resulted in a true detection rate of 57.7% and a false positive rate of 38.5% for 
one year survival. 
 
 
RAS/RAF mutations 
  
RAS and BRAF mutation status was available for 1,263 (78.8%) patients. Of these, 575 (45.1%) 
were RAS/RAF wild type; 587 (46.5%) were RAS mutated and 101 (8.0%) were BRAF mutated. 
There was clear evidence of an association between low dNLR and improved overall survival 
in each of these four groups (table 2). No evidence for a beneficial effect of additional cetuxi-
mab was demonstrated in any group of patients. 
 
Discussion 
Inflammation is well reported to contribute to tumour formation and is now a recognised 
hallmark of cancer. It is known that the tumour microenvironment can attract, educate and 
control invading leukocytes to promote angiogenesis, viability, motility and invasion. [16]  The 
stroma around solid cancers has been compared with a poorly healing wound and its' associ-
ated chronic inflammation. [17] The association of high NLR with worse survival is more pro-
nounced in metastatic than localised disease and therefore may reflect greater tumour bur-
den or a more prolonged chronic inflammatory process. [11] It is uncertain why NLR is more 
strongly associated with outcome than neutrophil or lymphocyte counts alone. This biological 
mechanism requires further investigation. Neutrophils may act as tumour-promoting leuko-
cytes through TGF-β, IL-10 and regulatory T-cells induced signal pathways and circulating 
neutrophils can also secrete the vascular endothelial growth factor (VEGF), resulting in higher 
levels of VEGF in the tumours. [18] High NLR may also represent a relatively depleted lym-
phocyte count, potentially impairing the host immune response to malignancy and therefore 
negatively impact outcomes. 
There is also evidence that RAS mutations influence the host immune response. KRAS and 
NRAS are critical components of intracellular signalling. Functional specificity of mutated RAS 
  
isoforms has been demonstrated and the role of mutant proteins in onset and progression of 
disease continues to be investigated. [19,20]  NRAS activation has been shown to suppress 
stress-induced apoptosis in human colorectal cancer cells lines and therefore contribute to 
colorectal cancer development. Mouse models also indicated that NRAS mutations enhance 
colon cancer development in the context of inflammation. [20]  
Recently, retrospective analysis investigated the relationship of NLR with molecular altera-
tions (KRAS/NRAS/BRAF/PIK3CA/CIMP) and circulating cytokines. [21] High NLR was associ-
ated with a poor prognosis in metastatic colorectal cancer, independent of the common mo-
lecular alterations. Similarly, in our study, the correlation between dNLR and survival was 
seen in all mutation groups. These results were consequently not predictive of benefit from 
the addition of cetuximab in any particular mutation group. Although modest, our results 
have shown a numerically poorer survival for patients with dNLR≥2.2 treated with additional 
cetuximab compared to those treated with chemotherapy alone. The BRAF mutated cohort 
was relatively small in number and underpowered. This data should therefore be interpreted 
with caution as this limits the ability to differentiate between prognostic and predictive value 
of dNLR in the context of chemotherapy with cetuximab. A meta-analysis with similar BRAF 
mutated cohorts may be of value. 
 
CRC patients with elevated NLR have been characterised by aggressive biology and distinctive 
expression profile of cytokines involved in angiogenesis, inflammation and regulation of the 
epidermal growth factor axis.  In the retrospective analysis, elevated NLR was >5. [21] There is 
ongoing statistical uncertainty with respect to the cut-off of elevated NLR and the subse-
quent interpretation of NLR as a prognostic and predictive biomarker. Our analysis confirms 
the prognostic value of dNLR in advanced colorectal cancer. We have demonstrated a strong 
  
association between dNLR with OS and PFS. dNLR is therefore moderately prognostic for one-
year survival in the COIN trial. This was independent of the treatment allocation arm. 
 
 
Conclusion   
Our study gives further support for the use of dNLR as a readily available, inexpensive bi-
omarker for prediction of survival in MCRC. We have demonstrated that in the randomised 
phase III COIN trial, dNLR was a reliable prognostic marker in patients with mCRC that re-
ceived first line oxaliplatin based chemotherapy with or without additional cetuximab. dNLR 
was strongly prognostic for survival in all mutations groups especially in patients with BRAF 
mutant tumours. dNLR was not predictive of benefit from cetuximab. 
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Figure 1 Kaplan–Meier curves for overall survival according to dNLR. 
  
Figure 2 Kaplan–Meier curves for overall survival according to treatment, in low (figure2a) 
and high (figure2b) dNLR. 
